{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-004159","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.872767+00:00","generated_at":"2026-06-20T17:39:07.383167+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"low","headline":"Kura Oncology reports preliminary cash balance of ~$438M as of Dec 31, 2022","bullets":["Preliminary unaudited cash, cash equivalents and short-term investments were approximately $438 million.","Cash balance is subject to completion of financial closing and audit; actual results may differ.","Company updated its corporate presentation materials (Exhibit 99.1), but substantive details not provided in filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-004159","json":"https://secwatch.observer/filing/0001193125-23-004159.json","markdown":"https://secwatch.observer/filing/0001193125-23-004159.md","text":"https://secwatch.observer/filing/0001193125-23-004159.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000119312523004159/0001193125-23-004159-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000119312523004159/d446484d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:39:07.383167+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}